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Objectives: The prevalence of osteoporosis fractures is anticipated to increase 
rapidly due to China’s aging population. However, representative data on the eco-
nomic burden of osteoporosis fractures are lacking. The aims of this study were to 
estimate direct outpatient medical costs, indirect costs and family burden associ-
ated with patients with osteoporosis fractures in China. MethOds: One hundred 
and fifty osteoporosis fracture patients and/or care-givers were interviewed within 
149 days [median] post-fracture in three tertiary hospitals in Beijing, Wuhan and 
Chongqing representing eastern, middle and western China. Fracture patients were 
discharged from hospital between January 2011 and January 2013. The survey col-
lected data on demographics; ambulatory status; outpatient services and costs 
(emergency room, drugs, other outpatient); indirect medical services and supplies 
and costs (nursing, transportation, rehabilitation, devices, etc.); and lost work time 
from caregivers. Results: Of the 123 valid respondents (female: 64.2%; mean age: 
71.3 years), 62.6% were hip fractures, followed by vertebral fracture (34.1%), non-
vertebral/non-hip fracture (2.4%), and multiple fracture (0.8%). All patients received 
surgical treatment, 8.9% had historical fractures, 80.5% had comorbidities and 82.9% 
of patients had post-discharge outpatient visits. The most frequent comorbidities 
were hypertension (61.0%), rheumatoid arthritis (41.5%), high cholesterol (35.0%) and 
cardiovascular disease (34.2%). Reported disability (walk w/aid or could not walk) 
increased from 13% pre-fracture to 36% post-fracture. Average post-acute outpatient 
care costs and indirect medical costs were 2084 RMB and 3526 RMB, respectively. 
Care-givers reported an average of 33.2 days lost from work. Using median income 
from the three regions, the estimated average lost income for caregivers was 5910 
RMB (weighted by share of responders per region). cOnclusiOns: The study sug-
gests the economic burden of osteoporosis fractures is considerable in terms of 
outpatient medical costs, indirect medical costs and family burden. Osteoporosis-
related fractures may pose a significant burden to China due to the aging population.
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Objectives: Provide clinically relevant evidence and drug expenditure informa-
tion for brazilian public health system management. MethOds: We performed a 
systematic review on the use of anti-TNF biological agents, infliximab, adalimumab 
and etanercept in the treatment of patients with rheumatoid arthritis, using the 
precepts of evidence-based medicine, ensuring methodological quality of clinical 
studies, prioritizing clinical outcomes. Clinical evidence was retrieved in PubMed, 
Central Cochrane, EMBASE and medicine purchase costs in July 2010. Results: 
Twenty-three randomized trials met the eligibility criteria, six on infliximab, nine 
on adalimumab and eight on etanercept. Adalimumab and etanercept showed no 
benefits when not associated with methotrexate. The ACR50 response to infliximab 
(NNT = 6) and adalimumab (NNT = 5) were similar while the results for etanercept 
were considered heterogeneous. The annual cost of infliximab to treat six patients 
and get ACR50 response in a single patient was US$ 125,997.00 while for adalimumab 
to treat five was US$ 186,990.00. The ACR70 response was similar between etanercept 
(NNT = 9) and adalimumab (NNT = 10), being lower in the recommended dose of 
infliximab (NNT = 12). The most favorable annual cost of acquisition was observed 
with adalimumab which US$ 311,651.00 is needed to treat 10 patients and get ACR70 
response in a single one, compared to expense of US$ 365,107.00 with etanercept 
(NNT = 9). The unusual infliximab dose of 10mg/kg showed similar results (NNT 
= 9), however with the most unfavorable spent of US$ 680,385.00. cOnclusiOns: 
Adalimumab was the agent who showed the most favorable annual expenditure 
for medicine purchase from the perspective of the public health system in Brazil, 
considering the most clinically relevant response.
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Objectives: To examine the pattern of biological treatment and the medical costs 
for patients with rheumatoid arthritis (RA). MethOds: A longitudinal dataset that 
includes the claims of service used by a cohort of RA patients from the Bureau of 
National Health Insurance was used for this study. The inclusion criteria for the 
study cases were patients who: 1) were holding the Catastrophic Illness Card with 
RA; 2) had the 1stline TNF-α antagonist treatments for at least 6 months; 3) were aged 
over 17. Treatment patterns were defined based on their TNF-α Antagonist within 
12 months after the initial 6-month treatment period. Wilcoxon signed rank tests 
were performed to compare differences in service costs and service uses between 
the pre- and post-biological treatment periods. Results: In total, 2425 patients 
were eligible for analysis. In the first year after TNF-α initial 6-month treatment, 94% 
remained using the same TNF-α antagonist, 3% had switched from one to another 
TNF-α antagonist, and 3% discontinued use of TNF-α antagonist. RA patients treated 
with TNF-α antagonist were significantly associated with reductions in emergency 
room visits (p < 0.001), hospital days (p < 0.01) and total medication costs (excluding 
biologics) (p < 0.01). However, total RA-related outpatient visits and overall medi-
cation costs went up significantly (p < 0.001). Reduction in services use was not 
productive age (18-60 for women and 18-65 for men) were recruited at regionally 
stratified sample of rheumatology outpatient centers around the country and 
were offered a questionnaire including Work Productivity and Activity Impairment 
(WPAI) instrument (a standardized tool for loss of work productivity estimation). 
The survey was complemented by disease activity assessment questionnaire 
filled out by specialists who were also responsible for patients recruitment dur-
ing the routine visits. Employed patients were estimating i.a. the absenteeism 
and presenteeism rates (% of work time missed due to health and % of impair-
ment while working). Subsequently, systematic review of Medline database was 
conducted. Two studies using WPAI questionnaire were found (Bansbrack 2012, 
Zhang 2010). Results: In the study, mean age of RA patients was 49 (mean age 
at RA onset was about 39), mean DAS28 result 3,77 (moderate disease). 40% of the 
group had first symptoms for less than 5 years (mean duration since symptoms 
onset was 90 months). Meanwhile, in Bansbrack 2012 mean age at RA onset was 
48 and mean duration since onset of symptoms was 48.6 months. Mean age of 
patients described in Zhang 2010 was 51, 45.8% had disease duration of less than 
5 years. The participants had a low function disability level and moderate arthritis. 
In the study absenteeism rate was 18%, while presenteeism rate reached 27%. The 
corresponding values in Bansbrack 2012 were 8.7% and 24%. In Zhang 2010 only 
presenteeism rate was analyzed and equaled 17.8%. cOnclusiOns: RA reduces 
work ability and lower work productivity in people in productive age both in Poland 
and in other countries. Differences in patients characteristics are probably the 
cause of results variation between studies.
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Objectives: Available data on economic impact of hip fractures in the U.K. are 
mostly derived from clinical trials or published before the year 2000; recent esti-
mates are lacking. This study examined health care resource usage, treatment and 
costs among patients with hip fracture in the U.K. MethOds: The study used data 
from the Clinical Practice Research Datalink (CPRD) linked to the Hospital Episode 
Statistics (HES). Adult patients hospitalised for hip fracture (ICD-10: S72 or M84.4; 
admission date as index date between January 1, 2006—March 31, 2011) and no pre-
vious hip fracture 7 days to 1 year pre- index, and computerised data available 1 year 
pre and 1 year post-index were identified in HES. Hip fracture-related inpatient and 
outpatient visits and pharmaceutical treatments were estimated for pre- and post-
index periods. Associated costs were calculated by multiplying resource units by 
official publicly available costs from the NHS perspective. Results: A total of 8,028 
hip fracture patients were identified (mean age 79; 27% age 85+; 75.8% female; mean 
Charlson comorbidity index score 2.1). The most common comorbidities were osteo-
arthritis (42%), pulmonary disease (25%), and renal disease (23%). Pre-index, aver-
age resource use per patient included 1 inpatient stay (mean 5.7 days), 7.4 General 
surgery visits, 4.4 blood tests, and 0.76 General Practice phone consults. Average 
overall costs pre-index were £3122. For the index hospitalisation, mean length-
of-stay and costs were 19.5 days and £14223, respectively; 18% were discharged to 
another hospital; and 39% and 5% had partial or total hip arthroplasty procedures 
performed. Post-index frequent medications included acetaminophen (56%), opioids 
(46%), and bisphosphonates (46%); 51% had hospital stays; and 5.7% had subsequent 
hip fractures. Average post-index overall costs were £7359. cOnclusiOns: Our 
study provides recent estimates of resource usage, treatment and costs among 
U.K. hip fracture patients. This information can be useful in burden of illness and 
economic analyses.
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Objectives: Total hip arthroplasty (THA) is a commonly performed surgical proce-
dure in the elderly, projected to increase substantially due to the aging population. 
Newer resource use and cost estimates are needed to understand the potential THA 
burden. The study objective was to estimate health care resource use and costs in 
THA patients in the U.K. MethOds: The Clinical Practice Research Datalink (CPRD) 
linked to the Hospital Episode Statistics (HES) was used to estimate resource use in 
THA patients. Inclusion criteria were: first inpatient stay for THA (OPCS procedure 
code W37-W39, W46-W48, W93-W95) (index event between 1/1/2006--3/31/2011); 
no THA diagnosis/procedure 7 days to one year pre-index date; 1-year pre and 
1-year post-index of computerised data available; age 18+. Inpatient, outpatient 
and pharmacy THA-related costs were calculated by multiplying resource units 
by official publicly available costs (British Pound Sterling, 2012) from the NHS per-
spective. Results: THA patients identified (n= 15,288) were mostly female (66%), 
elderly (mean age 72; 45%> 75), and 84% had osteoarthritis. Pre-index, the most 
common medications were opioids (53%), NSAIDs (41%), and acetaminophen (35%); 
95% had General surgery visits; 64% had inpatient stays; 36% had x-ray; and overall 
costs (std. dev) were £4,556 (7850). The index hospital event average length-of-stay 
(LOS) was 9 days and mean costs were £11,321. Post-index medication usage for 
opioids, NSAIDs, and acetaminophen was 49%, 29%, and 45%, respectively. The 
most frequent resources were General surgery visits (94%), hospital stays (39%), 
and General Practice phone consults (35%). For patients with utilisation, means per 
patient were 7.4 for General surgery visits, 5.4 days for hospitalisations. Mean (std. 
dev) overall post-index costs were £3,567 (9612), comprised mostly of inpatient costs 
(85%). cOnclusiOns: This study described resource utilisation, pain medications 
usage and associated costs for THA patients. These estimates may offer a better 
understanding of the economic burden.
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eligible for surgery, shows that HA viscosupplementation has the most favorable 
outcome, both from a clinical and economic point of view.
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Objectives: European registries of Rheumatoid Arthritis (RA) patients treated by 
biological agents suggest that 70-80% are maintained in first line at 1 year despite 
potential insufficient efficacy. Post hoc analyses of certolizumab pegol (CZP) stud-
ies indicate that a 3 month clinical response had a high predictive value of the 1 
year outcome. The objective was to examine the efficiency of a strategy consisting 
of early switching from CZP to a second line TNF inhibitor in case of insufficient 
clinical response at 3 months (3M) in the French setting versus current clinical 
practices. MethOds: A decision-tree model was built to estimate the clinical 
outcomes (ACR50 cumulated time) and the direct costs of different cohorts of RA 
patients over a 2 year period. ACR50 was considered as an RA satisfying clinical 
outcome. The “3M tight control” strategy consisted of stopping CZP at 3 months in 
patients not achieving the ACR50 criterion and switching them to other biologics. 
Three reference cohorts treated with first line CZP, etanercept or adalimumab, 
respectively, according to current clinical practices were considered as compara-
tors (reference). All TNF inhibitors were assumed to have equal efficacy in first line. 
Costs were estimated at 2013 French public prices. Results: The proportion of 
patients achieving ACR50 after a 2 year follow-up was 58% in all reference cohorts 
and 75% in the “3M tight control” CZP strategy cohort. The costs per patient-year 
in ACR50 were € 19,326 with the “3M tight control” strategy cohort and € 23,588, 
€ 26,774 and € 30,285 for the CZP, etanercept and adalimumab reference cohorts, 
respectively. The strategy “3M tight control” had an incremental cost-effectiveness 
ratio of € 5,605/patient-year in ACR50 versus CZP reference, and was dominant 
versus etanercept or adalimumab reference. cOnclusiOns: A 3-month tight con-
trol management of RA patients with CZP as first line treatment is cost-effective 
compared to alternatives.
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Objectives: To conduct a cost-per-responder analysis of biologic treatments 
(adalimumab, etanercept, golimumab, and infliximab) for the treatment of active 
ankylosing spondylitis (AS) from the German Statutory Health Insurants (SHI) 
perspective. MethOds: A systematic literature review was conducted to identify 
randomized clinical trials for biologic treatments for active AS. The clinical efficacy 
of biologic therapies and standard of care was evaluated using Assessment of 
SpondyloArthritis international Society (ASAS) 20 response, which is defined as at 
least 20% improvement from baseline using ASAS criteria. The relative probability 
of achieving ASAS 20 at Week 12 with each biologic therapy was estimated via net-
work meta-analysis. Evaluation was conducted in terms of cost-per-incremental 
ASAS 20 responder. Twelve-week costs were assessed in terms of 2012 euros, and 
included drug acquisition, administration, laboratory tests, and clinic visits based 
on German treatment guidelines. Weight-based dosing for infliximab assumed 
an average weight of 78.6 kg. Results: Thirteen randomized controlled trials of 
active AS with a minimal duration of 12 weeks were identified; 10 reported ASAS 
20 at Week 12. The estimated rates of ASAS 20 response at Week 12 were not sta-
tistically different between infliximab (70.8%), adalimumab (62.9%), golimumab 
(61.2%), and etanercept (60.5%). However, all 4 biologic therapies were significantly 
better than the standard of care (27.1%). In the base case, adalimumab had the 
lowest cost-per-incremental ASAS 20 responder compared with standard of care 
(€ 13,282 per incremental ASAS 20 responder), followed by golimumab (€ 13,947), 
etanercept (€ 14,221), and infliximab (€ 22,838). These rankings were unchanged 
in sensitivity analyses based on ASAS 40 response rates (estimated from 6 tri-
als). cOnclusiOns: All 4 biologic treatments were more efficacious in terms of 
ASAS 20 response than the standard of care. Among biologics, adalimumab showed 
the lowest cost per incremental ASAS 20 responder at Week 12 for active AS from 
the German SHI perspective.
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Objectives: To assess the cost-effectiveness of rituximab and anti-TNF-alfa 
agents in the treatment of Russian patients with rheumatoid arthritis (RA) who 
failed previous anti-TNF-alfa therapy. MethOds: The pharmacoeconomic model 
was developed based on the data from multicentre prospective 3-year observa-
tional MIRAR-study (J. Gomez-Reino et al., 2012). A one-year time horizon was 
adopted in the model. The cost analysis included costs of medicines and expenses 
for the day care services. The efficacy of therapies was defined as a reduction of 
disease activity score in 28 joints (DAS28) and proportion of patients achieved 
EULAR good or moderate response after 6, 9 and 12 months since biological 
therapy was started. To assess the robustness of the results, one-way sensitivity 
analysis (SA) was carried out. Results: Treatment with rituximab was associated 
significantly observed among patients who switched during their TNF-α antago-
nist treatment. cOnclusiOns: RA with biological treatment was associated with 
reductions of service uses; however, overall service costs were compromised by 
costs incurred from increased utilization of outpatient service and TNF-α antagonist 
medication costs under the context of health care in Taiwan.
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Objectives: Multicentric, open, retrospective study to determine whether NSAID 
consumption may be reduced by the use of US-guided Intra-articular injection 
(USGIAI) of hyaluronic acid (HA), in hip joint in patients affected by symptomatic 
hip OA. MethOds: Patients affected by mono or bilateral hip OA entered the study 
and were administered with a single HA (HyalOne-Hyalubrix 60) injection every six 
months. As primary endpoint, consumption of NSAIDs was evaluated by recording 
the number of days a month the patient used NSAID during the month previous to 
the visit, reported at each visit during the 24 months follow-up period, while second-
ary endpoints was represented by the percentage of patients assuming NSAIDs at 
baseline and at each control visit. Results: A total of 755 patients entered the study 
from 2008 to 2013. Consumption of NSAIDs was reduced from a consumption rate 
mean of 21,3 to a mean of 5,08 at the third month; this reduction further improved 
at 12th and 24th month with a reduction respectively to 4,14 and 3,79. Percentage 
of patients not taking NSAIDs at baseline was 45%; this percentage raised to 57% at 
12 months and remained stable (58%) at 24 months. We performed an evaluation of 
costs of therapies for hip OA for two hypothetic populations of 1000 patients each, 
the first one undergoing to HA USGIAI every six months for a total of 4 injections 
in 2 years, and the second one of 1000 patients undergoing to chronic daily NSAIDs 
therapy, both for two years. Our results confirmed in the USGIAI population a cost 
savings in comparison with the NSAIDs population. cOnclusiOns: HA USGIAI, 
administered every 6 months, reduce the assumption of NSAIDs in patients affected 
by hip OA, reflecting its efficacy on pain relief and cost saving.
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Objectives: To determine the clinical and pharmacoeconomic indicators from 
pharmacotherapeutic monitoring of patients using immunobiological (IMB) in 
a Health Insurance Company in Fortaleza - Brazil. MethOds: Cross-sectional 
study in two hospitals accredited Insurance, from March/2012 to May 2013 (n = 96 
patients). Data were recorded by medical (rheumatologist) in computerized manage-
ment system (Sabius ®) performed after the query. Later, these were entered into 
Microsoft Excell 2007 and analyzed by clinical pharmacists auditors. The cost was 
calculated from the unit value in the book Brasíndice 765, using the Consumer Price 
Maximum and average weight of 70 kg in standard doses. Results: Most patients 
were women (66, 68.75%), averaging 67 kg, aged between 30-59 years (62.50%) and 
higher incidence of rheumatoid arthritis among the diseases treated (45; 46.88%). 
The higher costs per capita were checked with Infliximab (R$ 62,459.40) and abata-
cept (R$ 41,989.55), while Adalimumab (R$ 16,614.60) and golimumab (R$ 10,385.05) 
represented the lowest cost per capita. There was a significant difference between 
the average cost per capita of IMB intravenous (91, R$ 48,975.27) and subcutaneous 
(11, R$ 10,695.49). The average cost for treatment / dose first line was R$ 6,068.91 
and the second line was R $ 9,590.06, resulting in an incremental cost / dose of R $ 
3,521.16 (36.72%). cOnclusiOns: The pharmacotherapeutic monitoring becomes 
important for planning strategies aimed at streamlining and optimization of these 
drugs and pharmacoeconomic clinical management.
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Objectives: Retrospective study to determine whether THR may be delayed by the 
use of US-guided Intra-articular injection (USGIAI) of hyaluronic acid (HA), in hip 
joint in patients affected by hip OA. MethOds: We evaluate the delaying in the 
THR considering 176 patients suffering from hip OA and treated with HA USGIAI, 
candidates for THR according to the judgment of six orthopaedics. Then, we imag-
ing two hypothetic populations of 1000 patients each candidates to THR, the first 
undergoing to 1 injection of HA (HyalOne-Hyalubrix 60) USGIAI and the second one 
undergoing to THR for a follow-up period of one year and four years. We performed 
the cost evaluation on hip surgery, eventual revision of the prosthesis, post-oper-
ative complications and mortality, rehabilitation, lost working days. Results: At 
24 months, 159 out of 76 (90 %) patients did not undergo to THR. At 48 months, 82 
% (N = 144) of the study population treated with HA USGIAI avoided THR. In the 
group of 93 patients candidates for THR (that is, in which 4, 5, or 6 orthopaedic 
surgeons agreed that the patient was a suitable candidate for THR), only 17 had 
undergone THR, with survival results of 82 % at 24 months. At 48 months, this 
percentage reduced to 66 % in this group. Results show that the treatment with 
HA USGIAI is the most favorable option, from a clinical and economic perspective, 
and also considering the social impact (higher value of quality-adjusted life-years 
(QALYs)). Analyzing hospital perspective, there are even higher benefits, estimated 
to be between approximately 940,000 euros in one year and 580,000 euros after 4 
years. cOnclusiOns: Data simulation comparing HA USGIAI vs THR in patients 
